Form D · Biotechnology
Biolexis Therapeutics Inc.
Lehi, UT · CIK 0001914060
Offering snapshot reported Jun 3, 2026 · SEC filing
- Reported sold
- $1.6M Offering amount: $12M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 20, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 3, 2026 | Initial | $1,600,000 | No comparison | 2 | SEC filing |
| Oct 17, 2023 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Oct 3, 2023 | Initial | $725,000 | No comparison | 6 | SEC filing |
| Sep 2, 2022 | Initial | $1,500,000 | No comparison | 2 | SEC filing |
| Mar 1, 2022 | Initial | $1,500,000 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-586088
Convertible Promissory Notes
Source: Form D, filed Jun 3, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dr. David J. Bearss | Director, Executive |
| David J. Bearss | Director |
| James N. Clarke | Director |
| Tyler Hartmann | Executive |
| Anthony Steve | Director |
| David O. Taylor | Director, Executive |
| Dr. Hariprasad Vankayalapati | Director, Executive |
| Hariprasad Vankayalapati | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3900 N Traverse Mountain Blvd Suite 200
Lehi, UT, 84043
Lehi, UT, 84043